Given that therapy-resistant cancer cells are particularly vulnerable to GPX4-targeted treatments, the potential of ferroptosis-inducing agents to enhance existing cancer therapies is promising (Wang L. et al., 2022). This evidence concerns the gene GPX4 and cancer.